We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 12, 2021

Neoadjuvant Chemoradiotherapy Plus Atezolizumab for Resectable Esophageal Adenocarcinoma

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Neoadjuvant Chemoradiotherapy Combined With Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single Arm Phase II Feasibility Trial (PERFECT)
Clin. Cancer Res 2021 Jan 27;[EPub Ahead of Print], T van den Ende, N Clercq, MI van Berge Henegouwen, SS Gisbertz, D Geijsen, R Verhoeven, SL Meijer, S Schokker, M Dings, JJGHM Bergman, N Haj Mohammad, JP Ruurda, R van Hillegersberg, S Mook, M Nieuwdorp, TD de Gruijl, TTD Soeratram, B Ylstra, NCT van Grieken, MF Bijlsma, MCCM Hulshof, HW van Laarhoven

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading